Neoadjuvant chemotherapy in patients undergoing neoadjuvant radiation for trunk and extremity soft tissue sarcoma

Abstract

AbstractIntroductionMany patients with high‐risk soft tissue sarcoma (STS) develop distant metastases. Meta‐analyses suggest that chemotherapy confers a small survival benefit, though few studies focus on neoadjuvant chemotherapy (NCT). There has been more frequent use of neoadjuvant radiation therapy (NRT) in STS, but the utility of NCT for these patients remains unclear.MethodsPatients with stage II−III trunk/extremity STS who underwent NRT and resection were identified using the National Cancer Database (2006−2019). Predictors of NCT were analyzed using logistic regression. Change in rate of NCT use over time was assessed using log‐linear regression modeling. Survival was examined using Kaplan−Meier (KM) and Cox proportional hazard modeling.ResultsOf 5740 patients, 25% underwent NCT. The overall median age was 62, 55% of patients were male, and 67% had stage III disease. The most common histological subtypes were fibrosarcoma/myxofibrosarcoma (39%) and liposarcoma (16%). Use of NCT decreased by 4.0% per year throughout the study period (p < 0.01). Predictors of NCT included younger age (median 54, IQR 42−64 vs. median 65, IQR 53−75, p < 0.01), treatment at an academic center (odds ratio [OR] 1.5, p < 0.01), and stage III disease (OR 2.2, p < 0.01). Histologic predictors of NCT included synovial sarcoma (52%) and angiosarcoma (45%). With a median follow‐up time of 77 months, NCT was associated with improved 5‐year survival compared to NRT alone on KM analysis (70% vs. 63%, p < 0.01). This difference persisted on multivariate analysis (hazard ratio 0.86, p = 0.027) and after propensity matching (70% vs. 65%, p = 0.0064).ConclusionDespite risk of distant failure in high‐risk STS, use of NCT has decreased over time in patients receiving NRT. In this retrospective analysis, NCT was associated with a modestly improved overall survival.